Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK CEO Garnier Rebuts Schering Prediction On Flonase OTC Switch

This article was originally published in The Pink Sheet Daily

Executive Summary

It is "bullish to say that the FDA is going to approve a switch in 2004," Garnier says in response to a statement by Schering CEO Hassan.

You may also be interested in...



Ivax Confident On Flonase Generic In 2004, Despite Bioequivalence Petition

Chicago law firm submits petition asking FDA to enforce standards in 2003 draft guidance on nasal inhalers. Client is unidentified, but is not GlaxoSmithKline. Ivax continues to expect approval of ANDA for fluticasone nasal spray this year.

US FDA's New Neurology Leadership Likely To Face Two Big Reviews In 2020

Eric Bastings will lead Division of Neurology I, which is expected to handle Biogen’s Alzheimer’s drug aducanumab and Sarepta’s refiling of golodirsen for DMD next year.

Topics

UsernamePublicRestriction

Register

PS058605

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel